Ascentage Pharma Group International vs Sinovac Biotech
AAPG and SVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and SVA compare
Sinovac Biotech grew revenue faster over the last twelve months (6.8% versus −41.5% for Ascentage Pharma Group International).
Sinovac Biotech scores higher on the StockData Score (6 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | SVA |
|---|---|---|
| Size and price | ||
| Share price | $14.62 | $6.47 |
| Change, 1 year | −55.6% | 0.00% |
| Change, 5 years | – | 0.00% |
| Beta (5Y) | 0.79 | 0.00 |
| Employees | 767 | 2,602 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 6.8% (better) |
| Revenue growth, 5Y average | – | −5.4% |
| EPS growth (TTM) | – | −165% |
| Profitability | ||
| Gross margin | 91.5% (better) | 67.9% |
| Operating margin | – | −127% |
| Net margin | −216% | – |
| FCF margin | −209% | −145% (better) |
| Return on equity | −156% | – |
| Financial health | ||
| Debt / equity | 1.50 (better) | 0.00 |
| Current ratio | 1.79 | 4.59 (better) |
| Dividends and buybacks | ||
| Years of dividend growth | – | 0 |
| Ownership | ||
| Held by institutions | 0.00% | 14.6% |
| Held by insiders | 13.0% | 65.7% |
| Short interest, % of float | – | 0.33% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- SVA stock overview
- SVA income statement
- SVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.